Crisis Of Low Supply, High Demand Means Big Opportunity
Right now helium is one of world's best investments. It's Earth's most nonrenewable resource and it's fast running out. That's a crisis because helium is a critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century's gadgets, appliances, and vehicles.
Get a free report that shows you how its supply
John Temperato, insider at 9 Meters Biopharma
John Temperato Insider Alerts

Get notified the next time John Temperato buys or sells 9 Meters Biopharma stock. Enter your email address below to get our daily insider buying and selling report.

John Temperato Insider Information

Mr. Temperato is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Prior to joining RDD, John held various leadership roles including, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015, when Salix was acquired by Bausch Health (NYSE: BHC) for ~$16 B. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience.

What is John Temperato's net worth?

The estimated net worth of John Temperato is at least $1.14 million as of August 18th, 2021. Mr. Temperato owns 1,102,522 shares of 9 Meters Biopharma stock worth more than $1,135,598 as of November 30th. This net worth approximation does not reflect any other investments that Mr. Temperato may own. Learn More.

How do I contact John Temperato?

The corporate mailing address for Mr. Temperato and other 9 Meters Biopharma executives is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. 9 Meters Biopharma can also be reached via phone at (919) 275-1933 and via email at [email protected]

Has John Temperato been buying or selling shares of 9 Meters Biopharma?

During the past quarter, John Temperato has bought $52,500.00 in shares of 9 Meters Biopharma stock. Most recently, on Thursday, November 18th, John Temperato bought 50,000 shares of 9 Meters Biopharma stock. The stock was acquired at an average cost of $1.05 per share, with a total value of $52,500.00.

Who are 9 Meters Biopharma's active insiders?

9 Meters Biopharma's insider roster includes Michael Constantino (Director), Mark Sirgo (Director), Edward Sitar (CFO), and John Temperato (CEO).

Are insiders buying or selling shares of 9 Meters Biopharma?

In the last twelve months, 9 Meters Biopharma insiders bought shares 10 times. They purchased a total of 676,529 shares worth more than $716,269.44. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 16,831,526 shares worth more than $20,492,393.96. The most recent insider tranaction occured on November, 18th when CEO John Temperato bought 50,000 shares worth more than $52,500.00. Insiders at 9 Meters Biopharma own 2.8 % of the company.

Information on this page was last updated on 11/18/2021.

John Temperato Insider Trading History at 9 Meters Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/18/2021Buy50,000$1.05$52,500.00View SEC Filing Icon  
8/18/2021Buy25,000$1.05$26,250.001,102,522View SEC Filing Icon  
4/5/2021Buy100,000$1.00$100,000.001,077,522View SEC Filing Icon  
8/21/2020Buy70,000$0.69$48,300.00615,496View SEC Filing Icon  
8/17/2020Buy35,000$0.57$19,950.00545,496View SEC Filing Icon  
6/15/2020Buy10,000$0.60$6,000.00
See Full Table

John Temperato Buying and Selling Activity at 9 Meters Biopharma

This chart shows John Temperato's buying and selling at 9 Meters Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

9 Meters Biopharma Company Overview

9 Meters Biopharma logo
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.
Read More

Today's Range

Now: $1.03
Low: $1.02
High: $1.06

50 Day Range

MA: $1.23
Low: $1.03
High: $1.41

2 Week Range

Now: $1.03
Low: $0.68
High: $2.26

Volume

1,284,778 shs

Average Volume

5,460,387 shs

Market Capitalization

$263.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!